Sham is a participant in the CAPTURE clinical trial, which aims to find out if women and men with hormone receptor-positive metastatic breast cancer, with an identified mutation in a gene called PIK3CA, can benefit from a new drug, alpelisib, in combination with fulvestrant.
Hormone receptor-positive metastatic breast cancers eventually become resistant to standard therapies such as endocrine therapy and CDK4/6 inhibitors (such as palbociclib, ribociclib or abemaciclib) and it is thought that mutations in the PIK3CA gene may be associated with resistance to these therapies. Mutations in the PIK3CA gene of cancer cells can be identified through a specialised blood test for circulating tumour DNA.
The study will investigate if the addition of alpelisib with fulvestrant for patients with a detectable PIK3CA gene mutation will improve progression-free survival and offer a new treatment option.
----------------------------------------------------------------
Breast Cancer Trials is a group of world-leading breast cancer doctors and researchers based in Australia and New Zealand committed to exploring and finding better treatments for people affected by breast cancer through clinical trials research.
Please like this video then visit www.breastcancertrials.org.au to find out more about our current breast cancer clinical trials that may be suitable for you, and ways in which you can help support breast cancer research.
----------------------------------------------------------------
SUBSCRIBE TO OUR YOUTUBE CHANNEL
[ Ссылка ]
LET'S CONNECT
Email ►enquiries@bctrials.org.au
Tel 1800 423 444
WWW ► [ Ссылка ]
Linkedin ► [ Ссылка ]
Twitter ► [ Ссылка ]
Facebook ► [ Ссылка ]
Instagram ► [ Ссылка ]
